Anti-MRSA β-lactams in development, with a focus on ceftobiprole: the first anti-MRSA β-lactam to demonstrate clinical efficacy

Abstract

Ceftobiprole is the first of the investigational β-lactam antibiotics with in vitro activity against methicillin-resistant staphylococci to reach and complete Phase III therapeutic trials. Its antibacterial spectrum includes methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus faecalis, penicillin-resistant streptococci and many Gram-negative pathogens. It has demonstrated in vivo activity against many experimental infections caused by these pathogens. Ceftobiprole has completed Phase III clinical trials for complicated skin and skin structure infections, is being studied in Phase III pneumonia trials and has demonstrated non-inferiority compared with vancomycin in a Phase III complicated skin and skin structure infections trial, resulting in > 90% clinical cures of infections caused by MRSA. Other anti-MRSA β-lactams in therapeutic clinical trials include the carbapenem CS-023/RO-4908463 and the cephalosporin ceftaroline (PPI-0903). The future of all of these agents will depend on their clinical efficacy, safety and their ability to be accepted as β-lactams for the reliable treatment of a broad spectrum of infections, including those caused by MRSA.

Keywords::

• ceftaroline
• ceftobiprole
• CS-023/RO-4908463
• MRSA

Disclosure

K Bush, M Macielag and G Noel are all employees of Johnson & Johnson Pharmaceutical Research & Development L.L.C. M Heep is an employee of Basilea Pharmaceuticals.